Replies to post #48755 on Cytodyn Inc (CYDY)

[ohm20]

Normally disable by HIV itself, we are protecting these key cells so any future rise of HIV in the body will be attacked by an individual’s immune system and HIV won’t be able to stop this reaction. Our AGT103-T HIV therapeutic drug should work to remove infected cells from the body and decrease or eliminate the need for lifelong antiretroviral treatment.

https://www.americangene.com/development-portfolio/hiv-aids/

Looking at their patents the claim to fight HIV seems a little odd.

A method of treating a cancer in a subject using an immunotherapy-based composition, the method comprising: administering a therapeutically-effective amount of an bisphosphonate drug to the subject; and administering a therapeutically-effective amount of the immunotherapy-based composition to the subject, wherein the immunotherapy-based composition comprises a lentiviral particle, the lentiviral particle comprising: a. an envelope protein capable of infecting one or more cancer cells, and b. at least one encoded shRNA capable of inhibiting production of an enzyme of the mevalonate pathway

Aminobisphosphonate drugs have also been used to stimulate GD T cells

Basically they're going to use a aminobisphosphonate drugs (like Fosamax - main use osteoporosis) to enhance T cells and inhibit farnesyl diphosphate synthase. Then use their genetically modified drug to break down the mevalonate pathway. The main drugs that break down the mevalonate pathway are statins.

Aminobisphosphonate drugs and statins have had very minor positive effects in cancer but have had no effect on HIV.

What really makes me think twice are the false claims they've made. Their drug does nothing to the CCR5 receptor and the CCR5 delta32 mutation does not reduce viral reservoirs because without a CCR5 receptor their are no reservoirs.

This news supports AGT’s research and development of an HIV cure in the form of a gene therapy product that replicates the effects of the CCR-5 mutation to reconstitute the immune response against HIV, by reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy, similar to the cured “London patient.”

https://www.americangene.com/press-releases/second-patient-cured-of-hiv-and-the-implications-for-american-gene-technologiess-agt103-t/